AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00289887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
Study NCT00698594 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sublingual allergen extract
Description: Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
Study NCT00698594 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sublingual allergen extract
Description: Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
Study NCT00698594 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
Study NCT03310073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: Batch Number: 2042015
Study NCT03310073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentabio
Description: Batch number: 5050115 The vaccine shall be given intramuscularly.
Study NCT03310073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: The vaccine shall be given intramuscularly.
Study NCT04392466 — intervention group
Intervention type: OTHER
Intervention: walking on the treadmill
Description: Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
Study NCT03362450 — intervention group
Intervention type: OTHER
Intervention: Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination
Description: Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
Study NCT03428425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel apatinib S-1
Description: HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery
Study NCT03178786 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PAT sessions
Description: PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
Study NCT03178786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT sessions
Description: PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
Study NCT04793919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: See the protocol
Study NCT04793919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: See the protocol
Study NCT04793919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic Trioxide
Description: See the protocol
Study NCT04793919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: See the protocol
Study NCT04793919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All-trans retinoic acid
Description: See the protocol
Study NCT03382964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
Study NCT04047043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum taurine
Description: blood sample for serum taurine level
Study NCT03004521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
Study NCT03004521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium prescribed in addition to the patient's existing antidepressant treatment.
Study NCT00720122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin like growth factor-1 (rhIGF-1)
Description: Twice daily
Study NCT01727245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Obese
Description: gastric bypass
Study NCT01727245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Cholecystectomy and anti-reflux surgery
Study NCT00908167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Please see detailed description.
Study NCT00908167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Please see Detailed Description.
Study NCT00908167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Please see Detailed Description.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
Study NCT01888445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: iv
Study NCT04644705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
Study NCT04644705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to the interventional drug
Study NCT03641326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
Study NCT03641326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3x-BT
Description: Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
Study NCT00163761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, vinorelbine, ifosfamide, filgastrim
Description: Drug
Study NCT00163761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, vinorelbine, filgastrim
Description: Drug
Study NCT00030394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00030394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00030394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04500990 — intervention group
Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d0.
Study NCT04500990 — intervention group
Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d8±1.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose: 200 mg by mouth daily for 28 a day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose: 15 mg by vein every week for a 28 day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by vein on day 1 of a 21 day cycle.
Study NCT01183663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
Study NCT01393782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
Study NCT01393782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angiotensin II
Description: All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
Study NCT04535674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion
Study NCT04500990 — intervention group
Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d30±2.
Study NCT04448444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Program Activating Therapy
Description: Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
Study NCT04448444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta reflex locomotion
Description: Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
Study NCT02295839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and Relaxation Education
Description: Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
Study NCT00953264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: lifestyle intervention, including diet, physical activity and behavioral changes
Study NCT04000568 — intervention group
Intervention type: OTHER
Intervention: Respiratory support: NAVA -NIV and PC-NIV
Description: The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
Study NCT01886911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Training Intervention Game
Study NCT01886911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prosocial Training Intervention Game
Study NCT01886911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control for Attention Intervention
Study NCT01886911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control for Prosocial Intervention
Study NCT00792896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family conference
Description: family conference
Study NCT02785341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires every 6 weeks (T0, T1, T2, T3 and T4)
Description: Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
Study NCT02785341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)
Study NCT02785341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: leptin level with a blood test every 12 weeks (T0, T2 and T4)
Description: blood sample
Study NCT02579954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study NCT00787657 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
Study NCT01259050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and Copper
Description: Optizinc 90 mg/d Copper 1 mg
Study NCT01143688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Study NCT02088671 — intervention group
Intervention type: DRUG
Intervention: Propofol induction followed by randomized doses of desflurane
Description: Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
Study NCT02088671 — intervention group
Intervention type: DEVICE
Intervention: Recording of EEG using NeuroSENSE
Description: The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest.
Study NCT02088671 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information.
Study NCT01143688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo inhaler
Study NCT01143688 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupuncture
Study NCT02077764 — intervention group
Intervention type: PROCEDURE
Intervention: OCT and coronary angiography
Study NCT02077764 — intervention group
Intervention type: PROCEDURE
Intervention: Right heart cat.
Study NCT02077764 — intervention group
Intervention type: RADIATION
Intervention: PET
Study NCT02077764 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Study NCT02077764 — intervention group
Intervention type: PROCEDURE
Intervention: exercise test
Study NCT02077764 — intervention group
Intervention type: OTHER
Intervention: blood samples
Study NCT01418274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses of danoprevir
Study NCT01418274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral doses of escitalopram
Study NCT01418274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses of ritonavir
Study NCT02088671 — intervention group
Intervention type: OTHER
Intervention: Drug: Emergence by stepping down the desflurane ET
Description: Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
Study NCT00384839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine for injectable suspension
Description: Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
Study NCT01981941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Description: Oral
Study NCT00449137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Study NCT00449137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Study NCT00449137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Study NCT00449137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma levels of elemental arsenic
Description: Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
Study NCT00449137 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis
Description: Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
Study NCT00449137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy (Fine-Needle Aspiration)
Description: Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
Study NCT03462732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Nasotracheal intubation will be done with endotracheal tube
Study NCT03462732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelaton catheter
Description: plus nelaton catheter